retatrutide triple hormone receptor agonist obesity for Phase 2 Trial of The data just dropped — triple-hormone-receptor agonist retatrutide for obesity

Side effect profiles are largely similar between oral and injectable semaglutide, with fewer than 10% of patients discontinuing due to adverse effects

Alternativas y estrategias para mantener resultados sin GLP-1 Aunque la evidencia sugiere que el tratamiento continuo con GLP-1 es generalmente necesario para mantener beneficios, existen estrategias que pueden ayudar a optimizar resultados y, en casos seleccionados, facilitar la transicin fuera del medicamento

High disease burden and continuous emergence of novel receptor-targeting molecules encourage robust product pipelines, contributing to sustained market penetration and commercial viability across multiple therapeutic classes

Caution notes Magnesium can cause loose stools in some people, especially citrate